Related Experiment Video
Updated: Jun 15, 2026

Differentiating Chondrocytes from Peripheral Blood-derived Human Induced Pluripotent Stem Cells
Published on: July 18, 2017
PHBV and predifferentiated human adipose-derived stem cells for cartilage tissue engineering.
Jiong Liu1, Bin Zhao, Yunqiang Zhang
1Department of Orthopaedics, The Fourth People's Hospital of Guiyang, Guiyang 550003, China.
This study explored whether human fat-derived stem cells, after being guided to become cartilage cells in the lab, could maintain that identity when placed in a specific type of scaffold called PHBV. The researchers implanted these cell-scaffold combinations under the skin of mice and observed them for 8 or 16 weeks. They found that the predifferentiated cells formed cartilage-like structures in the PHBV scaffolds, which remained intact for up to 16 weeks. The scaffolds degraded more slowly than expected, and the implants showed signs of cartilage formation like increased collagen and specific cell markers. However, the study also highlighted that the rate at which the scaffold breaks down in different environments needs more research. These findings suggest that PHBV could be a useful material for developing cartilage tissue in regenerative medicine.
Area of Science:
- Tissue engineering within regenerative medicine
- Stem cell biology in biomedical research
- Biomaterials development for orthopedic applications
Background:
Current research in tissue engineering seeks to develop reliable methods for cartilage regeneration. Prior studies have demonstrated that human adipose-derived stem cells (hASCs) can differentiate into chondrocytes in vitro. However, maintaining this differentiated state in a scaffold remains a challenge. While some scaffolds degrade too quickly, others fail to support long-term cell viability. This gap motivated researchers to explore whether predifferentiated hASCs could retain their chondrogenic properties when combined with a specific biomaterial. No prior work had resolved how scaffold degradation rates affect neocartilage formation in vivo. The need for a stable scaffold that supports long-term tissue development is clear. Existing approaches have not fully addressed the balance between scaffold longevity and cell activity. This study aims to fill that void by testing a specific polymer-scaffold combination. The field is moving toward more biocompatible and durable materials for tissue engineering applications.
Purpose Of The Study:
The study aimed to determine if predifferentiated hASCs could maintain their chondrogenic characteristics in PHBV scaffolds and if these constructs could form neocartilage in a heterotopic environment. Researchers focused on whether the chondrogenic phenotype could be preserved over time in a biocompatible scaffold. The specific problem addressed was the lack of long-term stability in cartilage tissue engineering constructs. By using a heterotopic implantation model, the team sought to simulate real-world tissue development conditions. The motivation stemmed from the need for durable and functional scaffolds in regenerative medicine. Previous studies had not fully examined scaffold degradation rates in different environments. This work sought to bridge that knowledge gap. The ultimate goal was to advance cartilage tissue engineering with a reliable scaffold-cell combination.
Main Methods:
The researchers first cultured hASCs in either chondrogenic or standard media to induce differentiation. The cells were then seeded onto PHBV foams to create cell-scaffold constructs. These constructs were implanted subcutaneously in nude mice for 8 or 16 weeks. A control group received nondifferentiated cell/PHBV implants. Histological analysis was used to assess cartilage formation and scaffold integrity. Gene expression was evaluated using RT-PCR to detect chondrocyte-specific markers. Scaffold degradation was monitored by tracking PHBV remnants in the implants. The study compared outcomes between differentiated and nondifferentiated cell groups. This approach allowed the team to evaluate both cell behavior and scaffold performance in vivo.
Main Results:
The control group showed no cartilage formation, and scaffolds degraded completely within 8 weeks. In contrast, differentiated hASCs/PHBV implants retained their shape for 16 weeks. At 16 weeks, these implants exhibited stronger histochemical staining for glycosaminoglycans (GAGs) and collagen. Compressive moduli increased with implantation time, indicating improved mechanical properties. Cartilage-like lacunae were observed in all 16-week implants. RT-PCR confirmed the presence of chondrocyte-specific genes at 16 weeks. PHBV remnants remained in the implants throughout the 16-week period. These findings suggest that predifferentiated hASCs can maintain their chondrogenic phenotype in PHBV scaffolds.
Conclusions:
The study shows that predifferentiated hASCs can maintain a chondrogenic phenotype in PHBV scaffolds for up to 16 weeks. Neocartilage formation was observed in the implants, with increased GAG and collagen levels over time. Cartilage-like structures were present at 16 weeks, as indicated by histochemical and gene expression data. Scaffold remnants were still detectable at the end of the study period. These results suggest that PHBV is a viable scaffold for cartilage tissue engineering. The findings support the use of predifferentiated hASCs in combination with PHBV for tissue regeneration. The study also highlights the need for further investigation into scaffold degradation rates in different environments. The authors propose that this approach could be useful for developing functional cartilage constructs.
Frequently Asked Questions
The study found that predifferentiated hASCs in PHBV scaffolds can maintain a chondrogenic phenotype and form neocartilage in a heterotopic site over 16 weeks.
PHBV serves as a biocompatible scaffold that supports chondrogenic cell differentiation and maintains structural integrity for up to 16 weeks in vivo.
Subcutaneous implantation provides a heterotopic environment to assess neocartilage formation and scaffold degradation in a controlled setting.
Histochemical staining showed increased GAG and collagen, and RT-PCR detected chondrocyte-specific genes in the implants at 16 weeks.
Scaffold degradation was tracked by observing PHBV remnants in the implants throughout the 16-week study period.
The authors noted that PHBV degradation rates in different environments require further investigation to optimize scaffold performance.

